Clinical Trial Detail

NCT ID NCT02991196
Title Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements no
Sponsors Daiichi Sankyo Inc.
Indications

colorectal cancer

Therapies

DS-8273a + Nivolumab

Age Groups: adult senior

No variant requirements are available.